Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Lymph node positive prostate carcinoma. A case for primary hormone therapy].

J E Altwein1

  • 1Urologische Abteilung, Krankenhaus der Barmherzigen Brüder, München-Nymphenburg.

Der Urologe. Ausg. A
|August 13, 1999
PubMed
Summary

For prostate cancer patients with lymph node metastases, immediate endocrine therapy may not always be necessary. Delayed hormone therapy can prolong time-to-progression without improving survival, suggesting careful consideration of treatment timing.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unusually large numbers needed to treat for radical prostatectomy in prostate cancer patients with PSA velocity ≤2 ng/ml/year.

Urologia internationalis·2012
Same author

[LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].

Aktuelle Urologie·2009
Same author

[Primary prevention of bladder cancer. What's new?].

Der Urologe. Ausg. A·2007
Same author

[Local recurrence of prostate cancer: hormone therapy].

Der Urologe. Ausg. A·2006
Same author

Biphosphonates in advanced prostate and renal cell cancer--current status and potential applications.

Urologia internationalis·2006
Same author

[Fortuitous finding microhematuria].

MMW Fortschritte der Medizin·2005

Area of Science:

  • Oncology
  • Urology
  • Medical Research

Context:

  • Lymph node metastases in prostate cancer often signify systemic disease.
  • Current local therapies (surgery, radiation) alone do not consistently alter outcomes for node-positive patients.
  • Early detection of lymph node involvement (diagnostic lead-time) can create a false impression of improved prognosis.

Purpose:

  • To evaluate the efficacy of different therapeutic strategies for prostate cancer with lymph node involvement.
  • To analyze the impact of immediate versus delayed endocrine therapy on survival and progression.
  • To explore alternative treatment concepts like intermittent hormone therapy.

Summary:

  • Radical prostatectomy or irradiation alone does not improve outcomes in node-positive prostate cancer.

Related Experiment Videos

  • While delayed hormone therapy may extend time-to-progression, it does not enhance cause-specific survival compared to immediate treatment.
  • Minimal lymph node metastases (pN1.1) might not require immediate endocrine intervention; intermittent hormone therapy offers potential benefits with fewer side effects.

    • Impact:

    • Findings suggest a re-evaluation of immediate endocrine therapy for select prostate cancer patients with lymph node metastases.
    • Highlights the limited survival benefit of delaying hormone therapy despite prolonged time-to-progression.
    • Supports further investigation into intermittent hormone therapy for long-term management and improved quality of life.